Stifel Cautious on Aardvark Therapeutics Inc (AARD) Amid 5% drop: 'without more clarity it's hard for us to get comfortable right now with the added uncertainty'
Tweet Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $6.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
